Mylan to pay $465 million over EpiPen Medicaid rebate dispute
EghtesadOnline: Mylan NV on Friday said it will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment, which has come under intense scrutiny after a series of drastic price increases.
|
Publish Date:09/October/2016 | 10:05